![](https://investorshub.advfn.com/uicon/496411.png?cb=1505403973)
Wednesday, July 10, 2024 10:05:59 AM
high standard deviation means the data points were all over the place. For example, one patient might have used zero opioid pills while another in the same group might have used 40 pills.
The curse of the small sample size. Hard to trust the results no matter which way they skew.
The question now, IMO, is whether BIEL can convince the CMS to reimburse for RecoveryRx under the NOPAIN Act without using this study from Ilfeld, because they absolutely cannot show this study to the CMS.
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM